Nutriband Cancels Planned Sale of Pocono Pharmaceuticals

The latest update is out from Nutriband ( (NTRB) ).

On February 13, 2026, Nutriband’s Board of Directors agreed to immediately terminate the planned sale of its subsidiary, Pocono Pharmaceuticals, Inc., to Earth Vision Bio Inc. The decision followed the buyer’s failure to pay required late fees after missing the December 31, 2025 closing date for the transaction.

Nutriband had received $30,000 in late fees but reported no additional payments since January 21, 2026, prompting the board’s action. The cancellation means Pocono Pharmaceuticals will remain under Nutriband’s control, potentially affecting the company’s portfolio strategy and any stakeholders who had anticipated the divestiture going ahead.

The most recent analyst rating on (NTRB) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Nutriband stock, see the NTRB Stock Forecast page.

Spark’s Take on NTRB Stock

According to Spark, TipRanks’ AI Analyst, NTRB is a Neutral.

Nutriband’s overall stock score is driven by a strong corporate event with positive market reception, offset by challenging financial performance and valuation issues. The technical analysis provides mixed signals, suggesting cautious optimism. The potential for shareholder value enhancement through recent corporate actions improves the score despite underlying financial weaknesses.

To see Spark’s full report on NTRB stock, click here.

More about Nutriband

Nutriband operates in the broader pharmaceuticals and drug delivery industry through subsidiaries such as Pocono Pharmaceuticals, Inc. The company’s activities include the development and commercialization of pharmaceutical products, positioning it within the healthcare and life sciences market with a focus on specialty therapeutics and related technologies.

Average Trading Volume: 34,101

Technical Sentiment Signal: Sell

Current Market Cap: $52.47M

For detailed information about NTRB stock, go to TipRanks’ Stock Analysis page.